therapeutics to improve cardiovascular health
Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries.
The History of VASCEPA®红9体育官方网站
Development of VASCEPA® leveraged Amarin’s extensive experience in the therapeutic benefits of polyunsaturated fatty acids and lipid science. The development of VASCEPA® challenged previously established understandings of the treatment of complex disease states and created an important new drug with the potential to significantly improve patient care for millions of patients. The use of VASCEPA® is supported by over 200 issued patents worldwide. VASCEPA® was designated by FDA as a new chemical entity in recognition of the drug’s novel single active ingredient. Similar designations have also been granted to VASCEPA®’s active ingredient in other jurisdictions internationally.MORE
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention MORE
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 MORE
- AMRN (NASDAQ)
- 4:00 PM on Jul 30, 2020
You may automatically receive Amarin Corporation plc financial information by email.